Incorrect description of mode of excretion of linagliptin
Hans-Juergen Woerle, Sanjay Patel
Boehringer Ingelheim GmbH, Germany
Dear Dr Zhou,
Boehringer Ingelheim, owner of the investigational drug linagliptin, would like to point out that in the recent review paper by Cox and colleagues,1 titled “Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy”, which was published in Drug, Healthcare and Patient Safety, the authors have incorrectly described the mode of excretion for linagliptin as being predominantly renal. The correct statement should have read: “Excretion of linagliptin is predominantly nonrenal”, as described in the referenced pharmacokinetic study performed by Heise and colleagues.2 A nonrenal elimination route may be important in patients with renal impairment, which is common in patients with type 2 diabetes, so this distinction may be of clinical relevance. We would be grateful if you could clarify this for your readership to help avoid any confusion.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.